Maravai LifeSciences reported a challenging third quarter in 2025 with total revenue decreasing by 39.7% year-over-year to $41.6 million and a net loss of $(45.1) million. The Nucleic Acid Production segment saw a significant decline due to a lack of high-volume CleanCap orders, while Biologics Safety Testing showed modest growth. The company remains optimistic about sequential revenue growth for TriLink in Q4 2025 and expects improved financial results in 2026.

Maravai LifeSciences experienced a challenging second quarter in 2025, with total revenue dropping to $47.4 million, a 31.7% decrease year-over-year, and a net loss of $(69.8) million, which included a $30.4 million goodwill impairment. The decline was largely attributed to reduced high-volume CleanCap orders. Despite this, the base business revenue, excluding high-volume CleanCap, grew 5%. The company has initiated a significant restructuring plan targeting over $50 million in annualized cost savings and appointed a new CEO and CFO to drive innovation and improve financial performance, with expectations of achieving net loss reduction, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026.

Maravai LifeSciences reported first-quarter 2025 revenue of $46.9 million, exceeding guidance. However, the company experienced a net loss of $(52.9) million and negative Adjusted EBITDA of $(10.5) million, primarily due to a lack of high-volume CleanCap orders and lower research product demand in Nucleic Acid Production, as well as a goodwill impairment charge.

Maravai LifeSciences announced the postponement of its Q4 and full year 2024 earnings release and conference call, originally scheduled for February 25, 2025. The delay is attributed to additional time needed for the year-end financial close process, including an assessment of a potential non-cash impairment charge related to goodwill, an identified revenue recognition error of approximately $3.9 million, and an assessment of the effectiveness of disclosure controls and internal controls over financial reporting.

Maravai LifeSciences reported a 2.5% decrease in revenue for the third quarter, totaling $65.2 million. The company experienced a net loss of $(176.0) million, which included a goodwill impairment of $154.2 million. They updated their full-year revenue guidance for 2024 to a range of $255.0 million to $265.0 million.

Maravai LifeSciences reported a 6.5% increase in revenue to $73.4 million for Q2 2024, driven by growth in Nucleic Acid Production. However, the company experienced a net loss of $(14.5) million and an Adjusted EBITDA of $16.9 million, both lower than the previous year. They reaffirmed their full-year revenue guidance of $265.0 million to $285.0 million.

Maravai LifeSciences reported a decrease in revenue to $64.2 million, a net loss of $(22.7) million, and an adjusted EBITDA of $7.8 million for Q1 2024. The company reaffirmed its full-year revenue guidance of $265.0 million to $285.0 million.

Maravai LifeSciences reported a Q4 2023 revenue of $74.1 million, a net loss of $(110.0) million, and an adjusted EBITDA margin of 28%. The revenue decrease was primarily driven by a significant decline in Nucleic Acid Production revenue, including COVID-19 related CleanCap revenue. The company is focusing on expanding its product portfolio and market leadership.

Maravai LifeSciences reported a 65% decrease in revenue for Q3 2023, driven by a significant drop in Nucleic Acid Production revenue due to lower COVID-19 related CleanCap demand and customer capital conservation efforts. The company is implementing a cost realignment initiative targeting $30 million in annualized cost reductions, including a workforce reduction of approximately 15%.

Maravai LifeSciences reported a 72% decrease in revenue for Q2 2023, totaling $68.9 million, driven by a significant decline in Nucleic Acid Production revenue due to lower COVID-19 related CleanCap demand. The company experienced a net loss of $(11.9) million and an Adjusted EBITDA of $9.1 million. Updated financial guidance for 2023 projects total revenue in the range of $300.0 million to $325.0 million.

Maravai LifeSciences reported a first-quarter revenue of $79.0 million, a net loss of $(1.3) million, and adjusted EBITDA margins of 30.1%. The revenue decrease was primarily driven by a decline in Nucleic Acid Production revenue due to decreased COVID-19 related CleanCap demand.

Maravai LifeSciences reported a decrease in revenue for the fourth quarter, driven by a decline in Nucleic Acid Production revenue due to decreased CleanCap demand. However, base Nucleic Acid Production revenue increased significantly. Net income and Adjusted EBITDA also decreased compared to the same period in the prior year.

Maravai LifeSciences reported a revenue of $191.3 million for Q3 2022, with a net income of $99.7 million and Adjusted EBITDA margins of 69%. The revenue includes $16.4 million from Biologics Safety Testing, $48.4 million from Nucleic Acid Production base business, and $126.5 million from COVID-19 related CleanCap® revenue.

Maravai LifeSciences reported a solid quarter with total revenues reaching $242.7 million, up 11% over the second quarter of 2021. The results include 27% revenue growth in the Nucleic Acid Production base business, after excluding the effect of an estimated $178 million of COVID-19-related CleanCap revenue in the quarter. Net income was $156.7 million for the second quarter, representing growth of 17% over the prior year.

Maravai LifeSciences reported a strong first quarter in 2022, with record quarterly revenue of $244.3 million, representing a 65% increase over the prior year. Net income also saw significant growth, reaching $146.9 million, a 95% increase over the prior year. The company has affirmed its revenue guidance and raised its adjusted EBITDA and adjusted EPS guidance for the full year 2022.

Maravai LifeSciences reported a strong fourth quarter with revenue of $228.4 million, a 132% increase over the prior year, and net income of $127.1 million, representing a 778% growth. The company's full-year revenue reached $799.2 million, up 181% from the previous year.

Maravai LifeSciences reported a strong third quarter with revenue increasing by 133% to $204.8 million and net income of $132.8 million, representing a 240% growth over the prior year. The company also increased its 2021 revenue guidance to a range of $770.0 million to $780.0 million and established initial 2022 revenue guidance range of $840.0 million to $880.0 million.

Maravai LifeSciences reported a significant increase in revenue for Q2 2021, driven by strong growth in its Nucleic Acid Production and Biologic Safety Testing segments. The company's net income also saw a substantial rise compared to the same period last year. Maravai updated its 2021 revenue guidance upwards and announced an agreement for the divestiture of its Protein Detection business segment.

Maravai LifeSciences reported a strong first quarter in 2021, with revenue increasing by 190.7% to $148.2 million, driven primarily by the Nucleic Acid Production business. Net income and Adjusted EBITDA were $75.9 million and $101.9 million, respectively.